US Patent 8,227,471: Scope of Claims, Effective Exclusivity, and Landscape Risk

US Patent 8,227,471 claims a method of treating hypoactive sexual desire disorder (HSDD) by administering flibanserin (or a pharmaceutically acceptable acid addition salt). The claims are drafted as treatment-use method claims with (i) broad patient coverage, (ii) layered dose ranges and unit strengths, and (iii) extensive salt recitations.

What is actually claimed?

What is the core claim scope (Claim 1)?

Claim 1 is a method claim with three limiting elements:

1) Disease/indication: “hypoactive sexual desire disorder”
2) Patient treatment method: “treating a patient… comprising administering”
3) Active ingredient: “therapeutically effective amount of flibanserin or a pharmaceutically acceptable acid addition salt thereof”

This is not a composition claim, not a manufacturing claim, and not a formulation claim in the strict sense. The infringement hook is using flibanserin (or an acid addition salt) to treat HSDD.

Claim 2 narrows the patient population:

“wherein the patient is male.”
This is a second, conditional dependent claim that creates a defined infringement lane if a party treats male HSDD.

How broad are dose and dosage-unit limits (Claims 3-12)?

Claims 3-12 add explicit quantitative boundaries. The claim set is unusually specific: it includes both daily mg ranges and per-dosage-unit mg. That increases clarity for infringement testing, but it can also create design-around opportunities if a competitor uses dosing outside these bands (depending on how doctrine of equivalents is applied in a given case).

Daily dose ranges (flibanserin free base or acid addition salt):

Claim 3: 0.1 to 400 mg/day
Claim 4: 1 to 300 mg/day
Claim 5: 2 to 200 mg/day

Dosage unit contents:

Claim 6: 0.01 to 100 mg per dosage unit
Claim 7: 0.1 to 50 mg per dosage unit
Claim 8: 150 mg per dosage unit (single strength)
Claim 9: 100 mg per dosage unit
Claim 10: 80 mg per dosage unit
Claim 11: 50 mg per dosage unit

Practical effect of this structure

The claim set is internally overlapping. The presence of both wide and narrower ranges means a wide swath of dosing strategies can fall within the asserted numbers.
The unit-strength claims (50, 80, 100, 150 mg) create bright-line targets. If competitors market a product with a different labeled strength and prescribe dosing that still uses those unit sizes or equivalents, it may still land in the method claim depending on dosing arithmetic.

How broad are salt recitations (Claims 12-24)?

The salt framework is a major scope lever. Claim 1 already covers “pharmaceutically acceptable acid addition salt.” Claims 12-24 hard-code a list and then carve out multiple exemplars.

Claim 12: salts formed by acids selected from:

succinic, hydrobromic, acetic, fumaric, maleic, methanesulphonic, lactic, phosphoric, hydrochloric, sulphuric, tartaric, citric
plus mixtures thereof

Claims 13-24: salt-specific dependent claims:

Claim 13: succinic acid
Claim 14: hydrobromic acid
Claim 15: acetic acid
Claim 16: fumaric acid
Claim 17: maleic acid
Claim 18: methanesulphonic acid
Claim 19: lactic acid
Claim 20: phosphoric acid
Claim 21: hydrochloric acid
Claim 22: sulphuric acid
Claim 23: tartaric acid
Claim 24: citric acid

Practical effect

If a competitor uses flibanserin in a salt form within this list, it is pulled into the claim family more directly.
If a competitor uses a different acid salt not listed in Claim 12, Claim 1 still covers “pharmaceutically acceptable acid addition salt thereof,” so the list is not the only cover. Claim 12 makes obvious that the applicants intended salt forms to be included, reducing room for an argument that some particular acid form is outside the “salt” concept.

How the claims map to infringement theories

What would constitute direct infringement in practice?

Because the asserted subject matter is “administering” to treat HSDD, the likely infringement theory centers on:

marketing and prescribing flibanserin for HSDD,
clinical administration consistent with the claimed daily mg ranges or per-dose-unit mg,
use of flibanserin in any acid addition salt form covered by Claim 1, with tighter coverage for the listed acids in Claims 12-24.

How do the dependent claims change litigation posture?

Dependent claims increase the number of alternative ways plaintiffs can establish infringement:

A defendant can attempt to argue that dosing does not match certain ranges, but the broader ranges (0.1-400 mg/day) can still capture many regimens.
A defendant may attempt to argue patient sex/indication. Claim 2 creates a lane specifically for male patients.
A defendant may attempt to argue “not the claimed salt.” Claim 1’s “pharmaceutically acceptable acid addition salt” language makes this a harder defense even if the salt is outside Claims 12-24, so salt defense may be more about factual chemistry (salt form in the product) than claim language.

Scope boundaries and potential design-around angles

Where is scope widest and where does it become fragile?

Widest

Claim 1: flibanserin or any pharmaceutically acceptable acid addition salt used to treat HSDD in a therapeutically effective amount.
Salt coverage: Claim 1 already covers acid addition salts generally; Claims 12-24 extend with explicit exemplars.

More fragile

The method claim is anchored to HSDD. Off-label use for a different sexual dysfunction would not be the claimed treatment.
If a competitor’s regimen uses flibanserin dosing outside claimed numeric ranges (particularly Claims 3-7), the dependent claims may be avoided, but Claim 1 still has the “therapeutically effective amount” anchor. In practice, if the regimen is therapeutic and still for HSDD, claim 1 can still be asserted even when a numeric-dependent claim fails.

What happens if a product uses non-acid salts?

The claims are limited to acid addition salts. If a competitor uses a salt that is not an acid addition salt (or a different salt category), they can attempt to argue outside Claim 1’s salt definition. But without the precise chemistry and without a broader base claim that covers free base only, the legal outcome depends on claim construction.

Patent landscape: what this patent likely fights in the US

How this patent typically functions in the US landscape

A US method claim for a known active ingredient is often asserted in a landscape where:

generic or alternative versions seek to launch quickly,
patent holders rely on method-of-use exclusivity to stop or delay entry,
litigations turn on whether the generic labels or promotional materials encourage the patented use.

In practice, the landscape around flibanserin in the US usually clusters around:

the original flibanserin treatment concept for HSDD,
subsequent flibanserin-specific claims that tighten dosing regimens or patient subsets (male),
any salt/formulation patents (to the extent they exist) that can interact with “administering” method claims.

What claim elements create litigation leverage against entrants

This patent’s leverage comes from three features:

1) Indication-specific method claim (HSDD)
2) Administration of flibanserin itself (no special formulation requirement)
3) Quantitative dosing and unit strength limits (Claims 3-11) plus explicit acid salt coverage (Claims 12-24)

These elements allow multiple independent infringement fact patterns to be presented.

Exclusivity and timing controls (what matters for business decisions)

What to key on for enforcement windows

For a US patent like 8,227,471, enforcement windows and freighting timelines typically turn on:

when the patent issued and whether any terminal disclaimers exist,
whether any exclusivity is tied to NDA approval periods (not shown in the claim text you provided),
whether there are overlapping patents in the same family and whether they cover:
- use,
- dosing,
- formulations/salts.

What this claim set suggests about remaining enforceability

Because Claim 1 is a classic method-of-use claim, it can remain useful as a “last mile” barrier if other composition/formulation patents expire earlier. If the rest of the family has narrower claims, this broad-use language can still anchor an enforcement posture.

Claim-by-claim scope table

Claim	Limitation	Scope effect
1	Treat HSDD by administering flibanserin or pharmaceutically acceptable acid addition salt in a therapeutically effective amount	Broadest independent coverage
2	Patient is male	Adds a defined subgroup path
3	0.1 to 400 mg/day	Broad dependent daily dosing band
4	1 to 300 mg/day	Narrower band within Claim 3
5	2 to 200 mg/day	Narrower band within Claim 4
6	Dosage unit 0.01 to 100 mg	Broad unit band
7	Dosage unit 0.1 to 50 mg	Narrower unit band
8	Dosage unit 150 mg	Specific strength
9	Dosage unit 100 mg	Specific strength
10	Dosage unit 80 mg	Specific strength
11	Dosage unit 50 mg	Specific strength
12	Acid addition salts formed by acids in listed set (succinic, hydrobromic, acetic, fumaric, maleic, methanesulphonic, lactic, phosphoric, hydrochloric, sulphuric, tartaric, citric; mixtures)	Defines included acids; supports salt disputes
13	Salt with succinic acid	Exemplifies included salts
14	Salt with hydrobromic acid	Exemplifies included salts
15	Salt with acetic acid	Exemplifies included salts
16	Salt with fumaric acid	Exemplifies included salts
17	Salt with maleic acid	Exemplifies included salts
18	Salt with methanesulphonic acid	Exemplifies included salts
19	Salt with lactic acid	Exemplifies included salts
20	Salt with phosphoric acid	Exemplifies included salts
21	Salt with hydrochloric acid	Exemplifies included salts
22	Salt with sulphuric acid	Exemplifies included salts
23	Salt with tartaric acid	Exemplifies included salts
24	Salt with citric acid	Exemplifies included salts

Key Takeaways

US 8,227,471 is a method-of-use patent: it targets administering flibanserin (or an acid addition salt) to treat HSDD.
Scope is broad at the independent claim level (Claim 1), because it covers therapeutic dosing and “acid addition salts” generally.
Dependent claims add numeric dosing and unit strengths (Claims 3-11) plus a broad acid set (Claims 12-24), improving infringement coverage across multiple dosing and salt-handling scenarios.
Business risk for entrants is highest where the product label, physician messaging, and clinical practice align with HSDD treatment using flibanserin within the claimed dose/unit structures, including for male patients (Claim 2).

FAQs

1) Does the patent protect flibanserin as a product or only the method of treating HSDD?

It claims methods of treating a patient with HSDD by administering flibanserin or an acid addition salt. The independent claim is not framed as a composition or manufacturing claim.

2) Are salt forms a major part of the claim scope?

Yes. Claim 1 covers pharmaceutically acceptable acid addition salts and Claims 12-24 list multiple specific acid salts. That reduces the ability to argue “not the same drug” based on salt selection if the salt is within the claimed categories.

3) Do the numeric dose limits control infringement for the whole patent?

The numeric ranges appear in dependent claims (Claims 3-11). Claim 1 still requires a “therapeutically effective amount,” so dosing compliance can still matter less than indication and flibanserin administration for the independent claim, but the dependent claims can strengthen enforcement.

4) Is male patient treatment included?

Yes. Claim 2 explicitly covers methods where “the patient is male.”

5) What is the landscape implication of a method claim like this?

A method claim can be used to challenge entry and use aligned with the patented indication, especially where labeling, promotional materials, and prescribing practices target HSDD with flibanserin.

References

[1] User-provided claim text for US Patent 8,227,471 (claims 1-24).

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	01125020	Oct 20, 2001

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	037109	⤷ Start Trial
Argentina	077480	⤷ Start Trial
Austria	327757	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,227,471

Summary for Patent: 8,227,471